Morristown (N.J.) Medical Center's GI medical oncology medical director Angela Alistar, MD, is leading research into Rafael Pharmaceuticals' CPI-613, a pancreatic cancer therapy.
Here's what you should know:
1. Dr. Alistar has been at the forefront of CPI-613 research. She conducted early stage clinical trials of the treatment and will serve as co-principal investigator on a phase-III combination therapy study of CPI-613 and modified Folfirinox.
2. In addition to this upcoming study, Dr. Alistar led four other clinical trials for CPI-613, as well as several for oncology drugs.
3. She said, "Pancreatic cancer has a very low survival rate. This is due in part to the fact that it is often discovered in a late stage. Early detection can make a difference."